- Home
- NRK vs PHAT Comparison
NRK vs PHAT Comparison
Compare NRK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRK
- PHAT
- Stock Information
- Founded
- NRK 2002
- PHAT 2018
- Country
- NRK United States
- PHAT United States
- Employees
- NRK N/A
- PHAT N/A
- Industry
- NRK Trusts Except Educational Religious and Charitable
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- NRK Finance
- PHAT Health Care
- Exchange
- NRK Nasdaq
- PHAT Nasdaq
- Market Cap
- NRK 884.6M
- PHAT 769.0M
- IPO Year
- NRK N/A
- PHAT 2019
- Fundamental
- Price
- NRK $10.08
- PHAT $12.98
- Analyst Decision
- NRK
- PHAT Strong Buy
- Analyst Count
- NRK 0
- PHAT 5
- Target Price
- NRK N/A
- PHAT $16.40
- AVG Volume (30 Days)
- NRK 187.3K
- PHAT 1.4M
- Earning Date
- NRK 01-01-0001
- PHAT 11-06-2025
- Dividend Yield
- NRK 4.10%
- PHAT N/A
- EPS Growth
- NRK N/A
- PHAT N/A
- EPS
- NRK N/A
- PHAT N/A
- Revenue
- NRK N/A
- PHAT $114,039,000.00
- Revenue This Year
- NRK N/A
- PHAT $213.11
- Revenue Next Year
- NRK N/A
- PHAT $91.84
- P/E Ratio
- NRK N/A
- PHAT N/A
- Revenue Growth
- NRK N/A
- PHAT 1049.82
- 52 Week Low
- NRK $8.95
- PHAT $2.21
- 52 Week High
- NRK $11.09
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- NRK 54.33
- PHAT 59.49
- Support Level
- NRK $10.10
- PHAT $11.49
- Resistance Level
- NRK $10.20
- PHAT $13.85
- Average True Range (ATR)
- NRK 0.08
- PHAT 1.04
- MACD
- NRK -0.03
- PHAT 0.15
- Stochastic Oscillator
- NRK 31.82
- PHAT 74.98
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.